Introduction
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells (PC) within the bone marrow. Clinically, patients with MM usually present bone pain related to lytic bone lesions, frequent anaemia and, less often, renal impairment. Despite improvements in the clinical management of patients in the past decade, especially with the use of high-dose therapy in the youngest patients, the disease remains ultimately fatal. However, this uniform evolution hides a tremendous heterogeneity, with patients inescapably evolving in a few weeks, while others may enjoy a more than 10-year survival. This prognostic heterogeneity is reminiscent from other haematological malignancies, like acute leukaemias, in which cytogenetics has been shown to directly drive evolution and survival. The idea was that genetics may define the natural history of tumours in general, but that this theory has been only demonstrated in some haematopoietic tumours, especially because of intrinsic characteristics (like easier cell availability, higher proliferation, or simpler oncogenesis).
Compared to acute leukaemias, very few large cytogenetic series have been reported. [1] [2] [3] [4] [5] Analysis of these series showed that karyotypes in MM are mostly normal. These data contrasted with other reports showing that DNA index or interphase fluorescence in situ hybridization (FISH) experiments were abnormal in more than 80% of the patients. [6] [7] [8] [9] [10] These discrepancies reflect the low proliferative index of PC. The median labelling index in MM is lower than 1%, 11 so much lower than that of the remaining normal bone marrow myeloid cells. Thus, because the bone marrow is usually only partially infiltrated by malignant PC, normal myeloid cells display a proliferative advantage, leading to an apparently normal karyotype in 60-70% of the patients with MM. This technical pitfall led some investigators to use other techniques, not based on proliferation, such as interphase FISH, to get an insight into MM oncogenesis. 9, 10, [12] [13] [14] However, this strategy presupposes to identify recurrent chromosomal abnormalities and to generate probes specific for these karyotypic changes.
Analysis of the cytogenetic literature
An extensive analysis of the cytogenetic literature revealed several recurrent cytogenetic abnormalities. The first finding was that informative (abnormal) karyotypes are usually highly complex, with two main subgroups: one represented by the gain of several chromosomes, defining hyperdiploidy, and a second subgroup characterized by pseudo-, hypo-or tetraploidy (gathered as nonhyperdiploid cases), with the accumulation of many structural chromosomal changes. Interestingly, hyperdiploidy (observed in about a half of the patients with abnormal karyotypes) was characterized by the gain of nonrandom chromosomes, especially odd chromosomes (3, 5, 7, 9, 11, 15, 19 and 21) . Hyperdiploid karyotypes present usually few structural changes. On the other hand, some chromosomes are frequently lost, especially chromosome 13 (in about half of the patients with an informative karyotype). Among the many structural abnormalities observed in the karyotypes, the most frequent are those involving the long arm of chromosome 1 (50%, not specific of MM) and the 14q32 chromosomal region (B30%). This low number of recurrent abnormalities opened the door to possible interphase FISH analyses using probes specific for these chromosomal changes.
14q32 abnormalities
The 14q32 chromosomal region is rearranged in several B-cell lymphomas, usually with specific chromosomal partners (for a review, see ). These translocations are almost constant, and are considered as primary events in the lymphomagenesis. In contrast, in MM they appeared to be much less frequent, until Bergsagel et al 16 reported that illegitimate rearrangements involving the gene encoding the Ig heavy chain (IGH), located at 14q32, were observed in almost 100% of human myeloma cell lines (HMCL). Moreover, they showed that most of these rearrangements involved switch sequences, raising the hypothesis of errors occurring during the switch process. These data prompted some authors to develop FISH probes specific for the IGH gene, enabling to look for illegitimate IGH rearrangements directly on interphase PC. 12, 17 The analysis of large cohorts of patients showed that cytogenetics largely underestimated the incidence of 14q32 abnormalities: 60-70% of patients with MM presented an illegitimate IGH recombination. 12, 17 However, in contrast to B-cell lymphomas, these chromosomal changes were not constant. The analysis of patients at relapse did not show a higher incidence, demonstrating that they were not secondary changes acquired during evolution. 17 On the other hand, they were observed with a similar incidence in monoclonal gammopathies of undetermined significance (MGUS), clearly showing that these genetic rearrangements were not sufficient for oncogenesis. 18 The analysis of a large number of HMCL revealed that three main 14q32 translocations were observed, each accounting for about 25% of the 14q32 rearrangements: t(11;14)(q13;q32), t(4;14)(p16;q32) and t(14;16)(q23;q32). Cloning of some of these translocations showed that t(11;14) involved the CCND1 gene on chromosome 11, leading to overexpression of cyclin D1 (similar to mantle cell lymphomas). 19 The role of cyclin D1 overexpression in the oncogenesis is not clear, since these MM do not present a proliferation higher than those lacking cyclin D1 activation. 20 Of note, PC bearing the t(11;14) present a peculiar lymphoplasmacytic morphology, reminiscent to mature PC. 20, 21 Translocation t(14;16) involved the c-maf oncogene on chromosome 16, deregulating the expression of the c-maf protein. 22 C-maf is a transcription factor that controls the expression of genes like CCND2, integrin-b7, or CCR1. 23 Its deregulation may lead to disturbances in the control of cell cycle, apoptosis, or cell-cell interactions. The situation appeared more complex for the t(4;14). The translocation deregulated two genes on chromosome 4: FGFR3 and, a novel gene, Multiple Myeloma SET (MMSET) domain. 24 Whereas FGFR3 is translocated on the der (14) and overexpressed, most of the MMSET exons remain on the der(4), leading to its abnormal expression in PC bearing the translocation. Two reports did show that FGFR3 was not always overexpressed in PC with the t(4;14), focusing the major role on MMSET. 25, 26 So far, the physiological role of MMSET is not known. As it contains a SET domain, this protein may play a role in the control of chromatin conformation.
The analysis of these specific 14q32 translocations in a large series of patients showed that the respective incidence of each of the three translocations was different from that observed in HMCL. 17, 27, 28 Whereas t(11;14) and t(4;14) were found in 15-20% of the patients each, t(14;16) was observed in less than 5% of the patients. This probably reflects differences in the potentialities of these translocations in generating cell lines in vitro. The analysis of MGUS also revealed some differences, t(4;14) and t(14;16) occurring very rarely in these individuals. 18, 25 However, other authors found different results, with a similar t(4;14) incidence in MM and MGUS. 29 Finally, these analyses showed that about half of the 14q32 translocations observed in patients did involve other chromosomal partners, probably not recurrent. Whether these latter 14q32 translocations are random and represent epiphenomena is an unresolved question.
Chromosome 13 deletions
Chromosome 13 presents frequent rearrangements in MM (about 50% of the patients with an abnormal karyotype), all leading to the loss of genetic material. Cytogenetic and comparative genomic hybridization studies identified a minimal common deleted region centred on the 13q14 region. [1] [2] [3] [4] [5] 13, 30, 31 However, it is important to keep in mind that about 90% of chromosome 13 abnormalities are total monosomies. 13, [30] [31] [32] Whether partial interstitial deletions produce similar biological significance is currently unknown. Nevertheless, analyses of large cohorts of patients using interphase FISH showed that half of the patients present a loss of this region, an incidence similar to that found with cytogenetics. 11, 13, 17, 33 In contrast to 14q32 translocations, which are observed in the large majority of the PC, chromosome 13 abnormalities may not be present in all the PC. In our experience, positive cases present a median of 75% of PC presenting the deletion, with a range varying from 20 to 100% (personal data, August 2004). These results favour the hypothesis of a secondary genetic event. However, other authors did not describe this variability. 13 This discrepancy is actually not resolved, but is apparently not explained by differences in technical methods.
Ploidy abnormalities
Besides these specific chromosomal abnormalities, more global chromosome changes are observed, that is, changes in the ploidy mode. Two subgroups can be identified: one subgroup characterized by the gain of chromosomes (448, usually 53-60 chromosomes), defining hyperdiploidy, and another subgroup presenting less than 48 chromosomes, defining nonhyperdiploidy (pseudo-and hypodiploidy). An extensive review of the cytogenetic literature revealed that each of these subgroups represents half of the patients with an informative karyotype. Hyperdiploidy is characterized by the gain of nonrandom chromosomes, especially odd chromosomes (3, 5, 7, 9, 11, 15, 19 and 21) . It is interesting to note that hyperdiploidy is also frequently observed in another B-cell malignancy, that is, childhood acute lymphoblastic leukaemia (ALL), but that in ALL extra chromosomes are essentially the even chromosomes. Why (and how) two B-cell malignancies present gains of different nonrandom chromosomes? No hypothesis is currently available to explain this bias in chromosome gains. Another characteristic of hyperdiploid karyotypes is the low incidence of structural chromosomal abnormalities. In contrast, nonhyperdiploid karyotypes are characterized by a high complexity and a frequent loss of chromosomes, especially chromosomes 13, 8, 14 and 16. Some of these nonhyperdiploid karyotypes present a few tetraploid metaphases, corresponding to the duplication of the pseudo-or hypodiploid clone.
Correlations between recurrent chromosomal abnormalities
As previously suggested, these recurrent chromosomal abnormalities are not randomly distributed, but present tight links. The first recognized association was the relationship between chromosome 13 loss and some 14q32 translocations. A chromosome 13 abnormality is observed in 85-90% of patients presenting a t(4;14) or a t(14;16), whereas it is present in 40-50% of other patients. 15, 25, 34 A similar association has been demonstrated between chromosome 13 and nonhyperdiploidy. 5, 26 Whereas monosomy 13 is observed in 30-35% of the patients with an hyperdiploid karyotype, it is present in about 85% of nonhyperdiploid patients. Finally, correlation of 14q32 translocations with ploidy revealed interesting findings. Most specific 14q32 rearrangements, that is, t(11;14), t(14;16) and, albeit to a lesser degree, t(4;14), are observed in nonhyperdiploid karyotypes (personal data, August 2004, and Fonseca et al 28 ) . In contrast, other nonrecurrent 14q32 translocations appear to be more frequent in hyperdiploid clones, strengthening the random character of these abnormalities. Thus, MM patients can be divided into two subgroups: one with mostly hyperdiploid karyotypes, with a low incidence of chromosome 13 abnormalities and of recurrent 14q32 translocations, and another group characterized by nonhyperdiploidy, a high incidence of deletions 13 and of recurrent 14q32 translocations.
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Impact on clinical management
Cytogenetics has become the most important prognostic factor in several haematopoietic tumours, especially in acute leukaemias. Several concordant data support a similar impact in MM.
The first implication of cytogenetics in survival has been the evaluation of chromosome 13 abnormalities. Many reports have demonstrated that patients presenting this factor displayed a shorter survival, independently of the type of treatment (conventional or high doses). 11, 27, 33, 35, 36 This pejorative impact seems to persist in the context of allogeneic bone marrow transplantation (personal data and Kroger et al . A matter of debate regards the technique used for its identification, that is, cytogenetics or FISH. It appears that chromosome 13 abnormalities are a more powerful predictor of poor outcome when identified on karyotype. 38 This finding probably reflects the sum of several pejorative prognostic factors, such as chromosomal abnormalities, chromosome 13 loss and high proliferation. Nevertheless, chromosome 13 abnormalities predict a poor prognosis even when identified by interphase FISH, which enables to detect much more positive patients (50 vs 15%). 27, 35, 39 More recently, the prognostic value of 14q32 translocations has been evaluated. Concordant data were obtained showing the poor prognosis associated with t(4;14), even with high-dose therapy. 25, 27, 40, 41 However, it is important to keep in mind that most t(4;14)-positive patients also present monosomy 13. Further large studies will be needed to evaluate the individual prognostic power of these two chromosomal abnormalities.
Other genetic lesions have been identified as predictors of longer survival. In contrast to previous cytogenetic studies, 42 t(11;14) has been shown to confer a better prognosis, especially for patients treated with high-dose chemotherapy. 41 However, numbers reported so far are quite small, and more extensive studies are warranted to definitely assess its prognostic value. Hyperdiploidy has also been associated with longer survival. 5 However, this conclusion has been obtained in patients presenting an abnormal karyotype (by definition), and should be confirmed by other series. Interestingly, recent reports have shown that patients with trisomy 11 displayed a high expression of cyclin D1, with levels close to those observed in the cases with t (11;14) . 43, 44 Since chromosome 11 is one of the most often gained chromosomes in hyperdiploidy, these data raise the question of the prognostic role of cyclin D1 expression in hyperdiploid cases.
Concluding remarks
Recent progresses in the evaluation of genetics in MM lead to a better understanding of MM oncogenesis. 45 The analysis of large series of patients enabled to clarify the position of individual chromosomal abnormalities, defining two types of MM. The first one is characterized by the gain of multiple specific chromosomes, a low incidence of chromosome 13 abnormalities and a low incidence of recurrent 14q32 translocations. This group would display quite long survivals, possibly related to high cyclin D1 expression. The second type of MM is characterized by the accumulation of multiple chromosomal breaks, pseudoor hypodiploidy, a high incidence of chromosome 13 losses and a high incidence of recurrent 14q32 translocations, especially t(11;14) and t (4;14) . Interestingly, this oncogenetic model fits quite well with data generated by expression microarray experiments. Even though this novel genomic test has not yet been extensively used in MM (essentially because of the need for PC purification), data analyses according to cyclin D1 and D2 expression generated a very similar model. 46 One group is characterized by cyclin D1 overexpression (gathering t(11;14)-positive and hyperdiploid cases), and a second group is characterized by cyclin D2 overexpression (gathering most other nonhyperdiploid cases, and especially t(4;14)-and t(14;16)-positive patients). These two oncogenetic models are very similar, and should allow a novel approach of MM. However, they both take into account only a part of the genetic heterogeneity observed in MM, and thus necessary reflect only a part of the biological diversity of the disease. Further large-scale analyses, including pan-genomic microarray studies are still warranted in order to better understand the pathophysiology of MM.
